TCR and CAR modified T cells as Cancer Immunotherapy – an overview – Emma Morris (University College London, UK)

Cancer killer profile: T cell fitness, autologous or allo T cell, Tcellor NK? – Jan Frič (Institute of Hematology and Blood Transfusion – UHKT, CZ)

Tumour and immunological environment influences in haematologic and solid tumours: engineering techniques or drug combination? – Victor Moreno (Start Madrid, ES)

Challenges in timely initiation and conduct of clinical trials in gene and cell therapies in hematoncology. From planning to trial authorisation to patient treatment and follow up

From clinical trials to marketing authorisation of advanced therapies – Martina Schuessler-Lenz (EMA CAT Chair; Paul-Ehrlich-Institut, DE)

Approval pathways for innovative gene & cell therapies – Adnan Jaigirdar (FDA, USA)

Clinical trials with gene and cell therapies – challenges and opportunities. The industry perspective – Laura Pearce (GSK, USA)

Challenges and learnings in conducting clinical trials with gene and cell therapies: the investigator perspective – Michael Hudecek (University of Würzburg, DE) – The speaker did not consent to have his presentation published

From marketing authorisation to patient access – the rollout from the industry perspective – Bernd Eschgfaeller (Novartis, CH) – The speaker did not consent to have his presentation published

Patient perspective – Kate Morgan (MPE, UK)

HTA perspective and reimbursement models – Carin Uyl-de Groot (Erasmus University Rotterdam, NL)

How can a collaborative CAR-T registry advance development? – Nicolaus Kroeger (Medical Center Hamburg-Eppendorf, DE)

Innovative concepts for clinical trials: Synthetic Control Arms – Emily Bratton (IQVIA, US)

Can Artificial Intelligence help to overcome current obstacles in CAR-T development? – Thomas Clozel (Owkin, FR)